Relapsing Chronic Myelogenous Leukemia (DBCOND0028987)

Identifiers

Synonyms
Not Available

Associated Data

Indicated Drugs and Targets
Not Available
Clinical Trials
IdentifierTitleDrug(s)PurposePhaseStatus
NCT00489203
Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancersupportive_care2completed
NCT01233921
Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancersupportive_careNot Availablecompleted
NCT00316953
Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylatetreatment1completed
NCT00890747
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapytreatment1completed
NCT00095797
XK469R in Treating Patients With Refractory Hematologic CancerNo drug interventionstreatment1completed
NCT01177371
High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphomatreatment2completed
NCT01558778
Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell TransplantNo drug interventionssupportive_careNot Availablewithdrawn
NCT00101088
Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemiatreatment1terminated
NCT00933985
Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemiatreatment1terminated
NCT00025415
Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunctiontreatment1completed
NCT00118352
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancertreatment2completed
NCT01305200
Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplantsupportive_care3completed
NCT00005799
Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney CancertreatmentNot Availablecompleted
NCT00006213
BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid Leukemiatreatment1completed
NCT00004918
Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrometreatment1 / 2completed
NCT01426334
Dasatinib and Cyclosporine in Treating Patients With Chronic Myelogenous Leukemia Refractory or Intolerant to Imatinib Mesylatetreatment1terminated
NCT01839916
Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignanciestreatment2completed
NCT00078858
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplanttreatment1 / 2completed
NCT01093586
Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignanciestreatment2completed
NCT00278330
Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory Anemiatreatment1completed
NCT00098826
SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromestreatment1completed
NCT01199562
Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell TransplantNot AvailableNot Availablecompleted
NCT00049192
Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemiatreatment2completed
NCT01159067
Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overloadsupportive_care2terminated
NCT00049504
Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancertreatment2completed
NCT00060372
Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancertreatment1completed
NCT00040846
Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignanciestreatment2completed
NCT00217412
Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemiatreatment1completed
NCT00459212
GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous Leukemiatreatment1completed
NCT00077181
3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic Malignanciestreatment1completed
NCT00408681
Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplantsupportive_careNot Availablecompleted
NCT01523223
Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignanciestreatment1completed
NCT00098423
Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromestreatment1completed
NCT00357708
Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer or Other Diseasestreatment1completed
NCT00702403
Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CMLtreatment1 / 2completed
NCT00005064
PS-341 in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia in Blast Phase, or Myelodysplastic Syndrometreatment1completed
NCT00006364
Homoharringtonine in Treating Patients With Chronic Phase Chronic Myelogenous Leukemiatreatment2completed
NCT01044745
Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancertreatment2terminated
NCT00052598
Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell Transplanttreatment1 / 2terminated
NCT00357305
Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorderstreatment1completed
NCT00799461
Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late ComplicationsNo drug interventionssupportive_care3completed
NCT00089011
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancertreatment2completed
NCT00856388
Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure DisorderstreatmentNot Availablecompleted
NCT00309907
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplanttreatment2completed
NCT01175785
Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignanciestreatment2completed
NCT01588015
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell TransplantNo drug interventionssupportive_care1completed
NCT01076270
Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic MalignanciestreatmentNot Availableterminated
NCT00331513
Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromestreatment1completed
NCT01231919
MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or LeukemiaNo drug interventionstreatment1completed
NCT01658319
Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignanciestreatment1completed
NCT00015834
STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemiatreatment1 / 2completed
NCT00084916
CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic Phasetreatment2completed
NCT00053963
FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemiatreatment1completed
NCT00387426
Sunitinib in Treating Patients With Idiopathic Myelofibrosistreatment2terminated
NCT00052520
Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantationtreatment1 / 2completed
NCT00101231
Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemiatreatment1terminated
NCT00054431
Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemiatreatment2completed
NCT00012376
Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancertreatment1completed
NCT01053494
Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for CancerNo drug interventionssupportive_careNot Availablecompleted
NCT00087204
Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemiatreatment1completed
NCT00301769
SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic Leukemiatreatment1terminated
NCT00795769
Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplantsupportive_care2completed
NCT01427881
Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignanciestreatment2completed
NCT01056614
Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Malignanciestreatment2completed
NCT01652014
Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignanciestreatment2withdrawn
NCT01789255
Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignanciessupportive_care2completed
NCT00381550
3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemiatreatment2completed
NCT00301938
7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromestreatment1completed